HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

rifapentine (Priftin)

Subscribe to New Research on rifapentine

cyclopentyl derivative of rifampicin

Also Known As:

Priftin; 3-(((4-cyclopentyl-1-piperazinyl)imino)methyl)rifamycin; 3-(((4-cyclopentyl-1-piperazinyl)imino)methyl)rifamycin SV; Aventis Behring brand of rifapentine; DL 473; DL 473-IT; DL-4-73; MDL 473; Rifapex

Networked: 129 relevant articles (8 outcomes, 32 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Peloquin, Charles A: 13 articles (08/2014 - 05/2003)
2.	Weiner, Marc: 12 articles (03/2015 - 08/2002)
3.	Nuermberger, Eric L: 12 articles (03/2015 - 12/2005)
4.	Grosset, Jacques H: 9 articles (08/2012 - 12/2005)
5.	Sterling, Timothy R: 8 articles (08/2015 - 06/2002)
6.	Tuberculosis Trials Consortium: 7 articles (08/2015 - 08/2002)
7.	Rosenthal, Ian M: 7 articles (08/2012 - 12/2005)
8.	Chaisson, Richard E: 6 articles (10/2015 - 04/2006)
9.	Vernon, Andrew: 6 articles (02/2015 - 06/2002)
10.	Dorman, Susan E: 6 articles (02/2015 - 11/2008)

Related Diseases

1.	Tuberculosis (Tuberculoses) 12/01/2005 - "To test this hypothesis we evaluated the sterilizing activity of improved once-weekly rifapentine-based continuation phase regimens in a murine model that mimics the treatment of high-risk patients with tuberculosis. " 08/01/2014 - "In this exploratory study, we characterized the free plasma fraction of rifapentine in 41 patients with tuberculosis. " 03/01/2010 - "Study 29 is currently underway, in which rifapentine was introduced in the experimental regimen for active tuberculosis treatment." 06/01/2004 - "The present pharmacokinetic study supports further trials to determine the optimal rifapentine dose for treatment of tuberculosis." 06/01/2002 - "We conducted a prospective, randomized, double-blind trial of rifapentine at three doses (600, 900, and 1,200 mg) plus INH 15 mg/kg once weekly in the continuation phase treatment of culture-positive tuberculosis in 150 human immunodeficiency virus-seronegative adults. "
2.	Infection 03/01/2015 - "Inhaled delivery of rifapentine has the potential to selectively enhance therapeutic efficacy at the pulmonary site of infection whilst minimising systemic exposure and related toxicity. " 03/01/2014 - "Recent animal studies have shown that more frequent administration of rifapentine could shorten treatment times, for both latent and active TB infection. " 10/01/1999 - "In this study, we evaluated the ability of rifapentine (RFP), in monotherapy and combination therapy, to completely eradicate a Mycobacterium tuberculosis infection and to prevent relapse posttreatment in a Swiss mouse model. " 06/01/2014 - "Update on cost-effectiveness of a 12-dose regimen for latent tuberculous infection at new rifapentine prices." 05/01/2014 - "A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection."
3.	Latent Tuberculosis 01/01/2011 - "Rifapentine-based regimens for treating latent tuberculosis infection (LTBI) are being considered for future clinical trials, but even if they prove effective, high drug costs may limit their economic viability. " 06/01/2002 - "Rifapentine 900-mg, once-weekly dosing appears to be safe and well tolerated and is being evaluated in Phase III efficacy trials of treatment of latent tuberculosis. " 09/01/1999 - "In this study we measured the efficacies of rifapentine-containing intermittent drug regimens for preventive therapy using the Cornell mouse model of latent tuberculosis. " 10/01/2015 - "Rifapentine for latent tuberculosis infection treatment in the general population and human immunodeficiency virus-positive patients: summary of evidence." 06/01/2014 - "Use of higher weight-adjusted rifapentine doses for young children are warranted to achieve systemic exposures that are associated with successful treatment of latent tuberculosis infection in adults."
4.	Pulmonary Tuberculosis 08/17/2002 - "Rifapentine once a week is safe and effective for treatment of pulmonary tuberculosis in HIV-negative people without cavitation on chest radiography. " 07/01/2015 - "Two-stage activity-safety study of daily rifapentine during intensive phase treatment of pulmonary tuberculosis." 05/15/2015 - "Erratum: daily rifapentine for treatment of pulmonary tuberculosis: a randomized, dose-ranging trial." 02/01/2015 - "We conducted a randomized, partially blinded dose-ranging study to determine tolerability, safety, and antimicrobial activity of daily rifapentine for pulmonary tuberculosis treatment. " 11/01/2005 - "This study was designed to describe the population pharmacokinetics of rifapentine (RFP) and 25-desacetyl RFP in a South African pulmonary tuberculosis patient population. "
5.	Hypersensitivity (Allergy) 01/01/1987 - "The purpose of this study was to determine the effect of rifampin and its cyclopentyl analogue, MDL 473, on delayed type hypersensitivity (DTH) using a murine model. " 01/01/1987 - "Effect of rifampin and its cyclopentyl analogue, MDL 473, on the expression of delayed type hypersensitivity to oxazolone." 03/01/2010 - "It would be of interest to profile rifalazil and analogs in relation to rifampin, rifapentine, and rifabutin in a variety of screens, particularly those that might relate to hypersensitivity or immunomodulatory processes."

Related Drugs and Biologics

1.	Isoniazid (Ftivazide)
2.	Rifampin (Rifampicin)
3.	Rifamycins
4.	1- (6- bromo- 2- methoxy- quinolin- 3- yl)- 4- dimethylamino- 2- (3- fluorophenyl)- 1- phenyl- butan- 2- ol (R207910)
5.	FCE 22807
6.	Pyrazinamide
7.	polylactic acid-polyglycolic acid copolymer (PLGA)
8.	Rifabutin (Ansamycin)
9.	moxifloxacin (Avelox)
10.	Ethambutol (Myambutol)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Microspheres (Microsphere)
3.	Directly Observed Therapy
4.	Transplants (Transplant)
5.	Retreatment